In addition to expression-based evidence of participation of CB1R and CB2R in AD, PD, and HD [8], mental disorders of anxiety and depression [9,46], psychosis [3] and PTSD [47], experimental evidence indicates that endocannabinoids participate in many other neuropathological disorders. This evidence concerns the gene CNR1 and depressive symptom measurement.